Abstract: SA-PO0856
Kidneys in the Crossfire: Insights into Renal Sarcoidosis
Session Information
- Glomerular Management: Real-World Lessons and Emerging Therapies
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Sindhoo, Zainah, Manchester University NHS Foundation Trust, Manchester, England, United Kingdom
- Meghji, Mohammed Askari Mujtaba, Manchester University NHS Foundation Trust, Manchester, England, United Kingdom
- Kanigicherla, Durga Anil K., Manchester University NHS Foundation Trust, Manchester, England, United Kingdom
- Elewa, Mohamed, Manchester University NHS Foundation Trust, Manchester, England, United Kingdom
- Gupta, Geetanjali, Manchester University NHS Foundation Trust, Manchester, England, United Kingdom
- Mohammed, Nazar I, Manchester University NHS Foundation Trust, Manchester, England, United Kingdom
- Mohammed, Ismail, Manchester University NHS Foundation Trust, Manchester, England, United Kingdom
Background
Renal Sarcoidosis is rare with an uncertain incidence and prevalence due to disease heterogeneity. It typically manifests with nephrocalcinosis and glomerular lesions, however, can vary. We aim to evaluate renal sarcoidosis and explore outcomes through a retrospective analysis at a tertiary centre in Manchester, UK.
Methods
A retrospective observational study with biopsy-proven kidney disease (KD) in Sarcoidosis, assessing demographics, presentation, histology, management, and outcomes over a median follow-up of 6 years. Adverse renal outcome (AO), progression to CKD 4 or 5 or requiring dialysis was the primary outcome. Univariate comparisons and regression analyses were used to identify predictors of poor outcome.
Results
Of the 32 patients, 44% presented with KD. In others, KD was noted on average 2.5 years after non-renal Sarcoidosis. 9 patients experienced AO; most were younger at presentation compared to the non-OA group (49.2 vs 61.8 years, p=0.041). There was no significant difference in sex, prior diagnosis, or multi-organ involvement. Granulomatous interstitial nephritis was the most common histology (55.6% vs 56.5%). Steroids were used in 78.1% of patients, predominantly prednisolone; 56% received high-dose regimen (≥30 mg/day). Patients with AO had lower eGFR at presentation (~20 vs 50 mL/min, p=0.04). By 100 months, 25% of patients relapsed, 4 progressed to ESKD and 3 died.
Conclusion
Renal sarcoidosis, is associated with adverse outcomes, and a return to baseline renal function is often not achieved. Aside from younger age and lower eGFR at presentation, there are no clear predictors of poor outcomes. Relapse rate and progression to ESKD highlight the need for proactive management. Prospective, multicentre studies are needed to refine prognostic tools and guide long-term care.